ReviewAnnals of medicine2025
Connexin 40 in atrial fibrillation: pathophysiological roles and regulatory mechanisms.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Th1/Th17-Treg Imbalance in Asian Atrial Fibrillation: Subtype and Demographic Heterogeneity.JACC. Asia · 2026Article
- Inflammation-Mediated Mechanisms of Arrhythmias After Acute Myocardial Infarction.Reviews in cardiovascular medicine · 2026Review
- Selective loss of Cx40 and conduction abnormalities underlie enhanced atrial fibrillation susceptibility in a HFpEF model in male mice.Physiological reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF), the most prevalent clinical atrial arrhythmia, arises from complex dysregulation of multicellular signalling pathways and molecular networks. Recent advances in cardiac electrophysiology have identified the atrial-specific gap junction protein Connexin 40 (Cx40) as a pivotal regulator of intercellular communication and cardiac electrical synchronization in AF pathogenesis. Aberrant Cx40 expression significantly disrupts atrial electrical conduction, yet its precise regulatory mechanisms remain incompletely understood. This review systematically examines the multifaceted roles of Cx40 in AF development, particularly focusing on how Cx40 genetic polymorphisms influence cardiac electrophysiology and promote atrial structural remodelling. Furthermore, we elucidate the ubiquitination-mediated protein degradation pathways governing Cx40 stability. These insights advance our understanding of AF pathophysiology and highlight potential therapeutic targets for precision arrhythmia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.